Charge-separated atmospheric neutrino-induced muons in the MINOS far detector

We found 140 neutrino-induced muons in 854.24 live days in the MINOS far detector, which has an acceptance for neutrino-induced muons of 6.91 x 10{sup 6} cm{sup 2} sr. We looked for evidence of neutrino disappearance in this data set by computing the ratio of the number of low momentum muons to the sum of the number of high momentum and unknown momentum muons for both data and Monte Carlo expectation in the absence of neutrino oscillations. The ratio of data and Monte Carlo ratios, R, is R = 0.65{sub 0.12}{sup +0.15}(stat) {+-} 0.09(syst), a result that is consistent with an oscillation signal. A fit to the data for the oscillation parameters sin{sup 2} 2{theta}{sub 23} and {Delta}m{sub 23}{sup 2} excludes the null oscillation hypothesis at the 94% confidence level. We separated the muons into {mu}{sup -} and {mu}{sup +} in both the data and Monte Carlo events and found the ratio of the total number of {mu}{sup -} to {mu}{sup +} in both samples. The ratio of those ratios, {cflx R}{sub CPT}, is a test of CPT conservation. The result {cflx R}{sub CPT} = 0.72{sub -0.18}{sup +0.24}(stat){sub -0.04}{sup +0.08}(syst), is consistent with CPT conservation

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

A Search for Lorentz Invariance and CPT Violation with the MINOS Far Detector

We searched for a sidereal modulation in the MINOS far detector neutrino rate. Such a signal would be a consequence of Lorentz and CPT violation as described by the Standard-Model Extension framework. It also would be the first detection of a perturbative effect to conventional neutrino mass oscillations. We found no evidence for this sidereal signature and the upper limits placed on the magnitudes of the Lorentz and CPT violating coefficients describing the theory are an improvement by factors of 20-510 over the current best limits found using the MINOS near detector

R-Process Alliance: 1st release in Galactic halo

VizieR online Data Catalogue associated with article published in journal Astronomical Journal (AAS) with title 'The R-Process Alliance: first release from the northern search for r-process-enhanced metal-poor stars in the Galactic halo.' (bibcode: 2018ApJ...868..110S

Metal-poor star RAVE J093730.5-062655 abundances

VizieR online Data Catalogue associated with article published in journal Astronomical Journal (AAS) with title 'The R-Process Alliance: discovery of a Low-{alpha}, r-process-enhanced metal-poor star in the Galactic halo.' (bibcode: 2019ApJ...874..148S